Acumen Pharmaceuticals (ABOS) Cash & Equivalents (2020 - 2026)

Acumen Pharmaceuticals has reported Cash & Equivalents for 7 years, with the latest figure at $51.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 70.43% year-over-year to $51.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.4 million (up 70.43% YoY) and the FY2025 annual result came in at $54.0 million, up 52.94% from the prior year.
• Cash & Equivalents fell to $51.4 million in Q1 2026 per ABOS's latest filing, from $54.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $157.5 million in Q3 2022 and troughed at $30.2 million in Q1 2025.
• A 5-year average of $72.1 million and a median of $66.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 201.81% in 2022, then sank 65.44% in 2024.
• Over 5 years, Cash & Equivalents stood at $130.1 million in 2022, then slumped by 49.12% to $66.2 million in 2023, then plunged by 46.68% to $35.3 million in 2024, then soared by 52.94% to $54.0 million in 2025, then retreated by 4.8% to $51.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $51.4 million, $54.0 million, and $46.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.